BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott. -
Treatment of Early FL More Effective With PET-Staging and Contemporary RT
Treatment of stage I/II follicular lymphoma (as determined by FDG-PET parameters) resulted in better freedom from progression and OS rates compared with historical numbers. -
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
VIDEO SERIES
LYMPHOMA NEWS
Molecular Characterization of Pediatric Follicular Lymphoma
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
SOX11 Status Not an Independent Prognostic Factor in Mantle Cell Lymphoma
Cure Rate Disparities Among Children With Burkitt Lymphoma
Textured Implants at Sites Other Than the Breast May Increase Risk of Implant-Associated ALCL
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
